Birmingham
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
Will Premier League with no fans be worth the wait?
The Premier League is adamant that it can overcome huge logistical challenges to get players back on the pitch during the coronavirus crisis but has long since accepted there will be no fans in the stadiums. English Football Association chairman Greg Clarke became the latest senior figure to admit this week that social-distancing guidelines make it impossible for supporters to congregate in stadiums “any time soon”. The drive behind the Premier League’s “Project Restart” is the attempt to avoid having to pay back millions in TV revenue. Clubs could reportedly miss out on £762 million ($946 million) for failing to complete this season alone. According to UEFA’s latest European Club Footballing Landscape report, just 13 percent of the Premier League’s revenue comes from gate receipts. Englan...
- 1
- 2
